Johnson & Johnson Reports Darzalex, Tremfya Growth with AAA Rating, 64-Year Dividend Streak
J&J spun off its consumer healthcare segment and posted rising Darzalex and Tremfya sales, while its expanding oncology pipeline and new drug approvals fuel growth. The company maintains a AAA credit rating higher than the U.S. Government and a 64-year dividend streak despite risks from patent expirations and talc litigation.
1. Consumer Healthcare Spin-Off and Strategic Focus
J&J completed the spin-off of its consumer healthcare segment, enabling greater focus on pharmaceuticals and medical devices. The separation generated proceeds and streamlined operations to allocate resources toward innovative drug development.
2. Strength in Oncology Sales and Pipeline Expansion
Johnson & Johnson reported notable sales increases from Darzalex and Tremfya, underscoring momentum in its cancer portfolio. The company secured approvals for multiple oncology candidates and advanced its pipeline to address unmet medical needs.
3. Strong Credit Profile and Dividend Track Record
The company holds a AAA credit rating, surpassing the U.S. Government’s rating, and has extended its dividend streak to 64 years. While this underscores financial resilience, J&J faces challenges from upcoming patent expirations and ongoing talc litigation.